Immunomic Therapeutics

Immunomic Therapeutics (ITI) is a biotechnology company pioneering the study of the universal intracellular targeted expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how immunotherapy is used for a number of diseases, including cancer, allergy, and infectious diseases.